Roche Holding | ROG - Selling And Administration Expenses


Roche Holding reported CHF6.37B in Selling and Administration Expenses for its fiscal semester ending in June of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.84B 205M Sep/2026
Alcon AG USD 964M 82M Jun/2026
Almirall -29.5M 4.72M Jun/2026
Amgen USD 1.68B 40M Sep/2026
AstraZeneca USD 4.07B 1.73B Sep/2026
Bayer EUR 4.02B 53M Sep/2026
Biogen USD 752M 42.3M Sep/2026
Bristol-Myers Squibb USD 1.7B 127M Sep/2026
Eli Lilly USD 3.12B 305M Sep/2026
Fresenius EUR 823M 63M Sep/2026
Fresenius Medical Care EUR 744M 7.99M Sep/2026
Genmab DKK 205M 39M Jun/2026
Gilead Sciences USD 1.52B 70M Jun/2026
GlaxoSmithKline GBP 2.16B 39M Sep/2026
GRIFOLS EUR 326M 37M Sep/2026
Hikma Pharmaceutical USD 288M 149M Dec/2025
Lakefront Biotherapeutics EUR 22.5M 13M Jun/2026
Merck EUR 1.58B 11M Sep/2026
Merck USD 2.86B 25M Sep/2026
Novartis USD 3.08B 163M Sep/2026
Orion EUR 98.9M 0 Sep/2026
Pfizer USD 3.28B 132M Sep/2026
Philips EUR 1.17B 33M Sep/2026
Recordati EUR 189.59M 12M Sep/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sanofi EUR 2.31B 325M Sep/2026
UCB EUR 1.47B 193M Dec/2025